The Effect of Lifestyle Intervention and Metformin on Preventing or Delaying Diabetes Among Women With and Without Gestational Diabetes: The Diabetes Prevention Program Outcomes Study 10-Year Follow-Up

被引:333
作者
Aroda, V. R. [1 ]
Christophi, C. A. [2 ]
Edelstein, S. L. [2 ]
Zhang, P. [3 ]
Herman, W. H. [4 ]
Barrett-Connor, E. [5 ]
Delahanty, L. M. [6 ,7 ]
Montez, M. G. [8 ]
Ackermann, R. T. [9 ]
Zhuo, X. [3 ]
Knowler, W. C. [10 ]
Ratner, R. E. [1 ]
机构
[1] MedStar Hlth Res Inst, Hyattsville, MD 20782 USA
[2] George Washington Univ, Ctr Biostat, Rockville, MD 20852 USA
[3] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Univ Calif San Diego, La Jolla, CA 92093 USA
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
[7] Harvard Univ, Sch Med, Boston, MA 02114 USA
[8] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[9] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[10] NIDDK, Phoenix, AZ 85014 USA
基金
美国国家卫生研究院;
关键词
ORAL GLUCOSE-TOLERANCE;
D O I
10.1210/jc.2014-3761
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Gestational diabetes (GDM) confers a high risk of type 2 diabetes. In the Diabetes Prevention Program (DPP), intensive lifestyle (ILS) and metformin prevented or delayed diabetes in women with a history of GDM. Objective: The objective of the study was to evaluate the impact of ILS and metformin intervention over 10 years in women with and without a history of GDM in the DPP/Diabetes Prevention Program Outcomes Study. Design: This was a randomized controlled clinical trial with an observational follow-up. Setting: The study was conducted at 27 clinical centers. Participants: Three hundred fifty women with a history of GDM and 1416 women with previous live births but no history of GDM participated in the study. The participants had an elevated body mass index and fasting glucose and impaired glucose tolerance at study entry. Interventions: Interventions included placebo, ILS, or metformin. Outcomes Measure: Outcomes measure was diabetes mellitus. Results: Over 10 years, women with a history of GDM assigned to placebo had a 48% higher risk of developing diabetes compared with women without a history of GDM. In women with a history of GDM, ILS and metformin reduced progression to diabetes compared with placebo by 35% and 40%, respectively. Among women without a history of GDM, ILS reduced the progression to diabetes by 30%, and metformin did not reduce the progression to diabetes. Conclusions: Women with a history of GDM are at an increased risk of developing diabetes. In women with a history of GDM in the DPP/Diabetes Prevention Program Outcomes Study, both lifestyle and metformin were highly effective in reducing progression to diabetes during a 10-year follow-up period. Among women without a history of GDM, lifestyle but not metformin reduced progression to diabetes.
引用
收藏
页码:1646 / 1653
页数:8
相关论文
共 17 条
  • [1] [Anonymous], 2002, Analysis of longitudinal data
  • [2] TRIPOD (TRoglitazone in the Prevention of Diabetes): A randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus
    Azen, SP
    Peters, RK
    Berkowitz, K
    Kjos, S
    Xiang, A
    Buchanan, TA
    [J]. CONTROLLED CLINICAL TRIALS, 1998, 19 (02): : 217 - 231
  • [3] Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
    Bellamy, Leanne
    Casas, Juan-Pablo
    Hingorani, Aroon D.
    Williams, David
    [J]. LANCET, 2009, 373 (9677) : 1773 - 1779
  • [4] 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study
    Bray, G. A.
    Chatellier, A.
    Duncan, C.
    Greenway, F. L.
    Levy, E.
    Ryan, D. H.
    Polonsky, K. S.
    Tobian, J.
    Ehrmann, D.
    Matulik, M. J.
    Clark, B.
    Czech, K.
    DeSandre, C.
    Hilbrich, R.
    McNabb, W.
    Semenske, A. R.
    Goldstein, B. J.
    Smith, K. A.
    Wildman, W.
    Pepe, C.
    Goldberg, R. B.
    Calles, J.
    Ojito, J.
    Castillo-Florez, S.
    Florez, H. J.
    Giannella, A.
    Lara, O.
    Veciana, B.
    Haffner, S. M.
    Montez, M. G.
    Lorenzo, C.
    Martinez, A.
    Hamman, R. F.
    Testaverde, L.
    Bouffard, A.
    Dabelea, D.
    Jenkins, T.
    Lenz, D.
    Perreault, L.
    Price, D. W.
    Steinke, S. C.
    Horton, E. S.
    Poirier, C. S.
    Swift, K.
    Caballero, E.
    Jackson, S. D.
    Lambert, L.
    Lawton, K. E.
    Ledbury, S.
    Kahn, S. E.
    [J]. LANCET, 2009, 374 (9702) : 1677 - 1686
  • [5] Bray GA, 1999, DIABETES CARE, V22, P623
  • [6] COX DR, 1972, J R STAT SOC B, V34, P187
  • [7] Gavin JR, 1997, DIABETES CARE, V20, P1183
  • [8] Gestational diabetes and the incidence of type 2 diabetes - A systematic review
    Kim, C
    Newton, KM
    Knopp, RH
    [J]. DIABETES CARE, 2002, 25 (10) : 1862 - 1868
  • [9] Knowler William C, 2002, N Engl J Med, V346, P393, DOI 10.1056/NEJMoa012512
  • [10] HbA1c as a Predictor of Diabetes and as an Outcome in the Diabetes Prevention Program: A Randomized Clinical Trial
    Knowler, William C.
    Edelstein, Sharon L.
    Goldberg, Ronald B.
    Ackermann, Ronald T.
    Crandall, Jill P.
    Florez, Jose C.
    Fowler, Sarah E.
    Herman, William H.
    Horton, Edward S.
    Kahn, Steven E.
    Mather, Kieren J.
    Nathan, David M.
    [J]. DIABETES CARE, 2015, 38 (01) : 51 - 58